Skip to main content


We're creating a new version of this page. See preview

Volume 3 Supplement 2

21st European Workshop for Rheumatology Research

  • Meeting abstract
  • Open Access

Antibodies to β2-glycoprotein I, prothrombin and antithrombin III as markers of the antiphospholipid syndrome severity

  • 1,
  • 1,
  • 2,
  • 2,
  • 1,
  • 3 and
  • 2
Arthritis Research & Therapy20013 (Suppl 2) :P084

  • Received: 15 January 2001
  • Published:


  • Public Health
  • Thrombocytopenia
  • Clinical Manifestation
  • Prothrombin
  • Prognostic Significance

Antibodies to β2-glycoprotein I /β2-GP I/, prothrombin /Pt/ and antithrombin III /AT III/ are not strictly speaking antiphospholipid antibodies, but they are closely associated with this pool of antibodies. The "marker" and prognostic significance of these antibodies have been recently widely discussed.

The aim of the presented study was to determine whether the anti-β2-glycoprotein I, anti-Pt and anti-AT III antibodies possess "marker" and prognostic value in APS syndrome.

The presence of the serum antibodies to these serum proteins, six selected phospholipids /including cardiolipin/ and Lupus antycoag-ulant have been tested and correlated with such clinical manifestations of the antiphospholipid syndrome /APS/ like: thrombotic events, fetal loss, trombocytopenia and livedo reticularis. The study covers 83 sera of the patients with various diagnoses /in 11 SLE, 43 SLE + APS /SAPS/ and 29 in PAPS/. The antibodies to β2-glycoprotein I in 21% of the SAPS cases and in 24% of the PAPS cases have been found and in none of the SLE without APS syndrome sera. The antibodies to Pt are present in 20% and to AT III in 15% of the tested sera. The correlation of antibodies to negatively charged phospholipid, LAC and anti-β2-glycoprotein I seems to be evident. Also significant increasing of the frequency of the appearance of selected clinical manifestations in the group of the anti-β2-glycoprotein I, anti-Pt and anti-AT III - positive sera was observed, especially fetal loss, livedo reticularis and thrombocytopenia. It seems to us the anti-β2-glycoprotein I, anti-Pt and anti-AT III antibodies are very promising "marker" for APS and possess also prognostic value.

Authors’ Affiliations

Institute of Rheumatology, Warsaw, Poland
Institute of Rheumatology, Moscow, Russia
Warsaw Agricultural University, Warsaw, Poland


© BioMed Central Ltd 2001